Cellectar Biosciences Inc ( (CLRB) ) has released its Q3 earnings. Here is a breakdown of the information Cellectar Biosciences Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company, focuses on developing proprietary drugs for cancer treatment using its Phospholipid Drug Conjugate™ (PDC) delivery platform.
In its third-quarter 2025 financial report, Cellectar Biosciences highlighted significant advancements in its drug pipeline, including plans to submit a conditional marketing approval application in Europe for iopofosine I 131, and the initiation of a Phase 1b study for CLR 125 targeting triple-negative breast cancer. The company also received a rare pediatric drug designation for iopofosine I 131 in treating pediatric high-grade glioma.
Key financial metrics revealed a decrease in both research and development expenses and general and administrative expenses compared to the previous year, resulting in a reduced net loss of $4.4 million for the quarter. The company raised approximately $12.7 million to support its ongoing projects and reported cash and cash equivalents of $12.6 million as of September 30, 2025.
Strategically, Cellectar is progressing with its iopofosine I 131 program, aiming for accelerated approval in the U.S. while advancing other promising candidates like CLR 225, which has shown potential in preclinical studies for pancreatic cancer.
Looking forward, Cellectar Biosciences remains committed to advancing its radioconjugate pipeline and pursuing regulatory approvals, positioning itself as a potential leader in targeted cancer therapies.